tetano
Editor, Senior Moderator
Thromb Res
. 2021 Dec 8;209:84-85.
doi: 10.1016/j.thromres.2021.12.004. Online ahead of print.
Safety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis
Aída Gil-Díaz[SUP] 1 [/SUP], Almudena Gil-Hernández[SUP] 2 [/SUP], Ana Isabel Lozano-Jiménez[SUP] 2 [/SUP], Jorge Benítez-Peña[SUP] 2 [/SUP], Alicia Conde-Martel[SUP] 3 [/SUP]
Affiliations
Abstract
Introduction: Cerebral venous sinus thrombosis (CVST) after coronavirus (COVID-19) vaccination has been reported. There are no data about thrombosis risk in prior CVST patients. The objective of the study was to describe short-term serious adverse events to COVID-19 vaccines in patients with history of CVST.
Material and methods: We present an observational prospective study of patients with known CVST who received COVID-19 vaccination. Serious event rates within 30 days after second dose vaccination (except one dose for Janssen) were evaluated, including recurrences, hospital admission and death.
Results: The 62 vaccinated patients received: BNT162b2 (Pfizer-BioNTech) in 43 patients (69.4%), mRNA-1273 (Moderna) in 7 patients (11.3%), AZD1222 (ChAdOx1) in 7 patients (11.3%) and Ad26.COV2.S (Janssen) in 5 patients (8.1%). There were no thrombotic recurrences within 30 days of vaccination (95% confidence interval, 0.0-5.8). There was one death (1.6%), not attributable to the vaccine.
Conclusions: COVID-19 vaccines are safe for previous CVST patients.
Keywords: COVID-19 vaccines; Cerebral venous sinus thrombosis.
. 2021 Dec 8;209:84-85.
doi: 10.1016/j.thromres.2021.12.004. Online ahead of print.
Safety of COVID-19 vaccination in patients with previous cerebral venous sinus thrombosis
Aída Gil-Díaz[SUP] 1 [/SUP], Almudena Gil-Hernández[SUP] 2 [/SUP], Ana Isabel Lozano-Jiménez[SUP] 2 [/SUP], Jorge Benítez-Peña[SUP] 2 [/SUP], Alicia Conde-Martel[SUP] 3 [/SUP]
Affiliations
- PMID: 34896915
- DOI: 10.1016/j.thromres.2021.12.004
Abstract
Introduction: Cerebral venous sinus thrombosis (CVST) after coronavirus (COVID-19) vaccination has been reported. There are no data about thrombosis risk in prior CVST patients. The objective of the study was to describe short-term serious adverse events to COVID-19 vaccines in patients with history of CVST.
Material and methods: We present an observational prospective study of patients with known CVST who received COVID-19 vaccination. Serious event rates within 30 days after second dose vaccination (except one dose for Janssen) were evaluated, including recurrences, hospital admission and death.
Results: The 62 vaccinated patients received: BNT162b2 (Pfizer-BioNTech) in 43 patients (69.4%), mRNA-1273 (Moderna) in 7 patients (11.3%), AZD1222 (ChAdOx1) in 7 patients (11.3%) and Ad26.COV2.S (Janssen) in 5 patients (8.1%). There were no thrombotic recurrences within 30 days of vaccination (95% confidence interval, 0.0-5.8). There was one death (1.6%), not attributable to the vaccine.
Conclusions: COVID-19 vaccines are safe for previous CVST patients.
Keywords: COVID-19 vaccines; Cerebral venous sinus thrombosis.